PURPOSE: Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer. Randomized trials with other regimens demonstrate that dose-dense (DD) scheduling can offer greater efficacy. We investigated the feasibility of administering CMF using a DD schedule. PATIENTS AND METHODS: Thirty-eight patients with early-stage breast cancer were accrued from March 2008 through June 2008. They were treated every 14 days with C 600, M 40, F 600 (all mg/m2) with PEG-filgrastim (Neulasta®) support on day 2 of each cycle. The primary endpoint was tolerability using a Simon's 2-stage optimal design. The design would effectively discriminate between true tolerability (as protocol-defined) rates of ≤ 60% and ≥ 80%. RESULTS: The median age was 52-years-old (range, 38-78 years of age). Twenty-nine of the 38 patients completed 8 cycles of CMF at 14-day intervals. CONCLUSION: Dose-dense adjuvant CMF is tolerable and feasible at 14-day intervals with PEG-filgrastim support.
PURPOSE:Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer. Randomized trials with other regimens demonstrate that dose-dense (DD) scheduling can offer greater efficacy. We investigated the feasibility of administering CMF using a DD schedule. PATIENTS AND METHODS: Thirty-eight patients with early-stage breast cancer were accrued from March 2008 through June 2008. They were treated every 14 days with C 600, M 40, F 600 (all mg/m2) with PEG-filgrastim (Neulasta®) support on day 2 of each cycle. The primary endpoint was tolerability using a Simon's 2-stage optimal design. The design would effectively discriminate between true tolerability (as protocol-defined) rates of ≤ 60% and ≥ 80%. RESULTS: The median age was 52-years-old (range, 38-78 years of age). Twenty-nine of the 38 patients completed 8 cycles of CMF at 14-day intervals. CONCLUSION: Dose-dense adjuvant CMF is tolerable and feasible at 14-day intervals with PEG-filgrastim support.
Authors: M N Fornier; A D Seidman; M Theodoulou; M E Moynahan; V Currie; M Moasser; N Sklarin; T Gilewski; G D'Andrea; R Salvaggio; K S Panageas; L Norton; C Hudis Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: Jeffrey L Halaas; Craig H Moskowitz; Steven Horwitz; Carol Portlock; Ariela Noy; David Straus; Owen A O'Connor; Joachim Yahalom; Andrew D Zelenetz Journal: Leuk Lymphoma Date: 2005-04
Authors: C Hudis; M Fornier; L Riccio; D Lebwohl; J Crown; T Gilewski; A Surbone; V Currie; A Seidman; B Reichman; M Moynahan; G Raptis; N Sklarin; M Theodoulou; L Weiselberg; R Salvaggio; K S Panageas; T J Yao; L Norton Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-02-13 Impact factor: 44.544
Authors: E Anders Kolb; Brian H Kushner; Richard Gorlick; Caroline Laverdiere; John H Healey; Michael P LaQuaglia; Andrew G Huvos; Jing Qin; Ha Thanh Vu; Leonard Wexler; Suzanne Wolden; Paul A Meyers Journal: J Clin Oncol Date: 2003-09-15 Impact factor: 44.544
Authors: Antonio Rueda; Pilar Sabin; Juli Rifá; Marta Llanos; José Gómez-Codina; Francisco Lobo; Ramón García; Joaquin Herrero; Mariano Provencio; Carlos Jara Journal: Hematol Oncol Date: 2008-03 Impact factor: 5.271
Authors: M Colleoni; H J Litman; M Castiglione-Gertsch; W Sauerbrei; R D Gelber; M Bonetti; A S Coates; M Schumacher; G Bastert; C-M Rudenstam; C Schmoor; J Lindtner; J Collins; B Thürlimann; S B Holmberg; D Crivellari; C Beyerle; R L A Neumann; A Goldhirsch Journal: Br J Cancer Date: 2002-06-05 Impact factor: 7.640